References
- Kauppinen R. Porphyrias. Lancet 2005; 365: 241–52
- Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol 1997; 44: 427–34
- Arbus MH. Relationship between porphyria and the use of antineoplastics. Am J Hosp Pharm 1981; 38: 631
- Palmieri C, Vigushin DM, Peters TJ. Managing malignant disease in patients with porphyria. QJM 2004; 97: 115–26
- Cochon AC, Aldonatti C, San Martin de Viale LC, Wainstok dC. Evaluation of the porphyrinogenic risk of antineoplastics. J Appl Toxicol 1997; 17: 171–7
- Schaffer M, Schaffer PM, Panzer M, Wilkowski R, Duhmke E. Porphyrias associated with malignant tumors: results of treatment with ionizing irradiation. Onkologie 2001; 24: 170–2
- Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889–95
- Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria. A case report and review of the literature. Support Care Cancer 2001; 9: 465–6
- Scarlett JD, Corry J, Jeal PN. Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP). Aust N Z J Med 1995; 25: 742–3
- Samuels B, Bezwoda WR, Derman DP, Goss G. Chemotherapy in porphyria. S Afr Med J 1984; 65: 924–6
- Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596–606